ASTM F1983-99 - 10.6.1999
 
1. Scope

1.1 This practice provides experimental protocols for biological assays of tissue reactions to absorbable/resorbable biomaterials for implant applications. This practice applies only to resorbable/absorbable materials with projected clinical applications in which the materials will reside in bone or soft tissue longer than 30 days and less than three years. Other standards with designated implantation times are available to address the shorter time periods. Careful consideration should be given to the appropriateness of this practice for slowly degrading materials that will remain for longer than three years. It is anticipated that the tissue response to degrading biomaterials will be different from the response to nonresorbable materials. In many cases, a chronic inflammatory response may be observed during the degradation phase, but the local histology should return to normal after degradation; therefore, the minimal tissue response usually equated with "biocompatibility" may require long implantations.

1. 2 The time period for implant degradation will vary depending on chemical composition and implant size; therefore, the implantation times for examination of tissue response will be linked to the rate of resorption. No single implantation time is indicated in this practice.

1.3 These protocols assess the effects of the material on the animal tissue in which it is implanted. The experimental protocols do not fully assess systemic toxicity, carcinogenicity, teratogenicity, or mutagenicity of the material. Other standards are available to address these issues.

1.4 To maximize use of the animals in the study protocol, all toxicological findings should be recorded. There are some aspects of systemic toxicity, including effects of degradation products on the target organs, that can be addressed with this practice, and these effects should be documented fully.

1.5 This standard does not purport to address all of the safety concerns, if any, associated with its use. It is the responsibility of the user of this standard to establish appropriate safety and health practices and determine the applicability of regulatory limitations prior to use.

 
2. Referenced Documents

F1903-18

Standard Practice for Testing for Cellular Responses to Particles in vitro

F1904-23

Standard Guide for Testing the Biological Responses to Medical Device Particulate Debris and Degradation Products in vivo

F1905-98

Standard Practice for Selecting Tests for Determining the Propensity of Materials to Cause Immunotoxicity

F1408-20a

Standard Practice for Subcutaneous Screening Test for Implant Materials (Includes all amendments and changes 9/1/2020).

F981-23

Standard Practice for Assessment of Muscle and Bone Tissue Responses to Long-Term Implantable Materials Used in Medical Devices

F763-22

Standard Practice for Short-Term Intramuscular Screening of Implantable Medical Device Materials

F750-20

Standard Practice for Evaluating Acute Systemic Toxicity of Material Extracts by Systemic Injection in the Mouse

F1906-98

Standard Practice for Evaluation of Immune Responses In Biocompatibility Testing Using ELISA Tests, Lymphocyte, Proliferation, and Cell Migration

F561-19

Standard Practice for Retrieval and Analysis of Medical Devices, and Associated Tissues and Fluids